1. Home
  2. APD vs ALNY Comparison

APD vs ALNY Comparison

Compare APD & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Products and Chemicals Inc.

APD

Air Products and Chemicals Inc.

HOLD

Current Price

$261.43

Market Cap

58.1B

Sector

Industrials

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$358.77

Market Cap

52.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APD
ALNY
Founded
1940
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1B
52.9B
IPO Year
1987
2004

Fundamental Metrics

Financial Performance
Metric
APD
ALNY
Price
$261.43
$358.77
Analyst Decision
Buy
Strong Buy
Analyst Count
12
27
Target Price
$284.27
$482.77
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
01-30-2026
02-12-2026
Dividend Yield
2.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.33
Revenue
$12,037,300,000.00
$3,210,070,000.00
Revenue This Year
$4.72
$70.40
Revenue Next Year
$5.94
$43.15
P/E Ratio
N/A
$1,121.71
Revenue Growth
N/A
53.24
52 Week Low
$229.11
$205.87
52 Week High
$341.14
$495.55

Technical Indicators

Market Signals
Indicator
APD
ALNY
Relative Strength Index (RSI) 54.24 34.07
Support Level $256.59 $348.13
Resistance Level $267.22 $376.87
Average True Range (ATR) 5.98 16.74
MACD 0.09 -1.16
Stochastic Oscillator 58.92 13.65

Price Performance

Historical Comparison
APD
ALNY

About APD Air Products and Chemicals Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated roughly $12 billion in revenue in fiscal 2025.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: